BioXcel Therapeutics Inc (NASDAQ: BTAI) kicked off on November 20, 2023, at the price of $4.14, down -7.26% from the previous trading day. During the day, the shares moved up to $4.25 and dropped to $3.73 before settling in for the closing price of $4.13. Over the past 52 weeks, BTAI has traded in a range of $2.23-$34.12.
While this was happening, its average annual earnings per share was recorded 3.61%. With a float of $20.22 million, this company’s outstanding shares have now reached $28.15 million.
In an organization with 183 employees, it is important to assess its efficiency. In terms of profitability, gross margin is +7.47, operating margin of -42242.93, and the pretax margin is -44246.40.
BioXcel Therapeutics Inc (BTAI) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of BioXcel Therapeutics Inc is 30.94%, while institutional ownership is 35.19%. The most recent insider transaction that took place on Jun 16, was worth 605,501. In this transaction CEO and President of this company sold 30,000 shares at a rate of $20.18, taking the stock ownership to the 39,903 shares. Before that another transaction happened on Jun 15, when Company’s CEO and President sold 30,000 for $21.54, making the entire transaction worth $646,226. This insider now owns 39,903 shares in total.
BioXcel Therapeutics Inc (BTAI) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/29/2023, the organization reported -$1.72 earnings per share (EPS), lower than consensus estimate (set at -$1.3) by -$0.42. This company achieved a net margin of -44201.87 while generating a return on equity of -111.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.61% per share during the next fiscal year.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators
Take a look at BioXcel Therapeutics Inc’s (BTAI) current performance indicators. Last quarter, stock had a quick ratio of 2.45. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 90.41.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -7.36, a number that is poised to hit -0.90 in the next quarter and is forecasted to reach -2.06 in one year’s time.
Technical Analysis of BioXcel Therapeutics Inc (BTAI)
Let’s dig in a bit further. During the last 5-days, its volume was 3.26 million. That was better than the volume of 1.96 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 31.42%. Additionally, its Average True Range was 0.61.
During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 15.73%, which indicates a significant decrease from 20.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 155.91% in the past 14 days, which was higher than the 152.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.38, while its 200-day Moving Average is $14.14. However, in the short run, BioXcel Therapeutics Inc’s stock first resistance to watch stands at $4.14. Second resistance stands at $4.46. The third major resistance level sits at $4.66. If the price goes on to break the first support level at $3.62, it is likely to go to the next support level at $3.42. The third support level lies at $3.10 if the price breaches the second support level.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats
The company with the Market Capitalisation of 112.10 million has total of 29,273K Shares Outstanding. Its annual sales at the moment are 380 K in contrast with the sum of -165,760 K annual income. Company’s last quarter sales were recorded 460 K and last quarter income was -53,520 K.